Digital genome is a complete digital set of genetic material that present in an organism or a cell. Digital genome technology deals with genes and their functions to find the causes behind the chronic diseases and also to fix them. The technology is associated with the advancements that help to make healthcare more personal and more effective for the treatment. Moreover, the digital genome is an easier way of gathering information about the chronic disease. The technology is used by the professionals to get a closer look of genetic composed diseases, such as cancer. Digital genome acts as a supporter that enables instant access to trait combinations to solve apparently endless custom queries.
Programming is associated with a high level of abstraction; biology, on the other hand, deals with a great deal of detail. That’s why their symbiosis has so much potential: these sciences complement each other. But there are very few people who understand both. And, in my experience, researchers who are able to work at the intersection of sciences are the most valuable staff. There are many such symbiotic sciences today, but computer science is included in most of these pairs. Humanity exists in a digital world, and thus it’s easier to store and analyze information in the digital format.
Image Credit: news.itmo.ru
In 1975, scientists proposed the first methods of DNA sequencing, i.e. the extraction of data from the genome. The first full human genome was made public in 2001, and the research cost billions of dollars. Today, we can decrypt a full genome for $1,000. This is made possible by the increased efficiency of sequencing machines; now, scientists can procure the same amounts of data in much shorter times.
Sequencing results in a massive amount of DNA data. Scientists call the entirety of one genome’s data the DNA library. But analyzing that library manually is a problematic task. Bioinformatics specialists develop new algorithms to determine the initial position of each gene. For instance, they’ve developed mapping software, which identifies the proper gene sequence and the relative distance between nodes in a linkage group.
Growing Funding for Genomics
Genomic sequencing technology is rapidly transitioning into clinical practice, and implementation of the same into healthcare systems has been supported by substantial government investment, accounting for ~US$ 4 billion in at least 14 countries. These national genomic-medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption, thereby driving the market growth. Moreover, the UK has announced the world’s largest genome project as part of 200 million public–private collaboration between charities and pharmaceuticals. The UK has already developed the largest genome database in the world through the 100,000 Genomes Project. Led by Innovate UK as a part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently.
One application for the findings of such research is in the treatment of antibiotic resistance. Resistance to antibiotics has two common causes: in one case, the patient has not completed their treatment and ended it halfway through. In such an event, the surviving bacteria end up becoming resistant to the medical product in question. In the other case, there is an external source of resistance. Poorly prepared meat of animals treated with antibiotics may contain bacteria with a cultivated resistance. The danger is that there are fewer than ten types of antibiotics in the world. According to even the best-scenario forecasts, 300 million people will die due to antibiotic resistance in the future.
Additionally, companies are focusing on supplying superior quality instruments to research centers and pharmaceutical companies that are involved in developing therapies for genetic diseases. For instance, Thermo Fisher Scientific announced the launch of its Ion Torrent Genexus System, the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day.
THERMO FISHER SCIENTIFIC INC., F. HOFFMANN-LA ROCHE LTD, Illumina, Inc., QIAGEN, GenomeMe, NanoString Technologies, Inc., BD, bioMerieux SA, GenMark Diagnostics, Inc., and Perkin Elmer, Inc. are among the leading companies operating in the digital genome.